SB
CHRS icon

Samsara BioCapital’s Coherus Oncology CHRS Stock Holding History

Samsara BioCapital’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.8M Hold
3,428,571
– – 0.39% 22
2026
Q1 		$5.79M Buy
+3,428,571
New +$6.09M 0.56% 20

Other funds holding CHRS

TGY2IT
Timothy G. Youngquist 2020 Irrevocable Trust Fort Myers, Florida $510M AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Samsara BioCapital's CHRS Position: Q2 2026 in Review

Samsara BioCapital held its Coherus Oncology (CHRS) position steady in Q2 2026 at 3,428,571 shares worth $4.8M. The position accounts for 0.39% of the portfolio, ranked #22.

Samsara BioCapital first reported a position in CHRS in Q1 2026 and has held it in 2 quarters since. The position peaked at $5.79M in Q1 2026. 147 funds tracked by Wall St. Rank hold CHRS as of Q2 2026.

  • Samsara BioCapital held 3,428,571 shares of Coherus Oncology worth $4.8M as of Q2 2026.
  • Samsara BioCapital left its Coherus Oncology share count unchanged in Q2 2026.
  • Coherus Oncology made up 0.39% of Samsara BioCapital's portfolio in Q2 2026, its #22 holding.
  • Samsara BioCapital first reported a position in Coherus Oncology in Q1 2026 and has held it in 2 quarters since.
  • Samsara BioCapital's Coherus Oncology position peaked at $5.79M in Q1 2026.
  • 147 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2026.

Based on Samsara BioCapital's 13F filing for Q2 2026, filed 14 Aug 2026.